FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Jacques Rachelle Suzanne
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2024		 3. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [AKTX]
(Last)
(First)
(Middle)
C/O AKARI THERAPEUTICS, PLC, 22 BOSTON WHARF ROAD FL 7		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

BOSTON, MA 02210		 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares, par value $0.0001 per share 538,457,900 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (2) 06/01/2032 Ordinary Shares, par value $0.0001 per share 207,634,400 $ 0.0124 D  
Stock Option (Right to Buy)   (2) 07/29/2032 Ordinary Shares, par value $0.0001 per share 29,762,300 $ 0.0124 D  
Stock Option (Right to Buy) 06/01/2023(3) 06/01/2033 Ordinary Shares, par value $0.0001 per share 152,690,700 $ 0.0016 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Jacques Rachelle Suzanne
C/O AKARI THERAPEUTICS, PLC
22 BOSTON WHARF ROAD FL 7
BOSTON, MA 02210		   X     Chief Executive Officer  

Signatures

/s/ Rachelle Jacques 01/02/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Securities beneficially owned totaling 538,457,900 includes 153,397,775 ordinary shares, par value $0.0001per share ("Ordinary Shares") owned and 385,060,125 of unvested time-based restricted stock units held by the Reporting Person.
(2) The stock option award was granted under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on March 28, 2022, subject to continued service with the Issuer.
(3) The stock option award was granted under the Issuer's 2014 Plan. The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on June 1, 2023, subject to continued service with the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.